Edition:
United States

Vanda receives negative opinion for marketing authorization from the European Medicines Agency


Friday, 10 Nov 2017 04:05pm EST 

Nov 10 (Reuters) - Vanda Pharmaceuticals Inc ::Vanda receives negative opinion for marketing authorization from the European Medicines Agency on fanaptum™ for the treatment of schizophrenia.Vanda Pharmaceuticals Inc - ‍CHMP re-examined its negative opinion and confirmed refusal of fanaptum MAA​.